ClinicalTrials.gg
CompletedNCT05399940Updated Jun 1, 2022

The Relationship Between Serum PSA Levels and WBC, Delta Neutrophil Index (DNI) and Other Hematological Parameters

An observational study in Prostate Infection, Prostate Disease and Prostate Cancer, sponsored by Hisar Intercontinental Hospital. Completed at 1 site in Turkey. Open to male participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-01.

Primary conditionProstatic NeoplasmsRegistry: Prostatic DiseasesReclassifiedWhy we changed it
Registry
Prostatic Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Prostatic Neoplasms
Why
  1. The study's listed conditions name Prostatic Neoplasms, a narrower term within Prostatic Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hisar Intercontinental Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
250
Ages
18 Years to 90 Years
Sex
Male
01

Study summary

Purpose:

To find the correlation between hemogram parameters and Delta Neutrophil Index(DNI) and Serum PSA in patients presenting with the diagnosis of acute prostatitis.

Material-Metod: Serum PSA levels and hemogram parameters of patients who came to the urology outpatient clinic in January 2018 and May 2022 and were diagnosed with prostatitis were collected retrospectively.

Read the detailed description

Serum PSA levels and hemogram parameters of patients who came to the urology outpatient clinic in January 2018 and May 2022 and were diagnosed with prostatitis were collected retrospectively.

WBC, neutrophil, lymphocyte, neutrophil-lymphocyte ratio, delta neutrophil index (DNI), PLT, RDW, and MPV values were determined in the Hemogram Parameters. Serum Total PSA and Free PSA values of the patients were also checked. Urine culture, urinary ultrasound, and antibiotic therapy

02

Conditions studied

  • Prostate Infection
  • Prostate Disease
  • Prostate Cancer

Browse trials for

Keywords

  • prostatit
03

In context

Prostatic Neoplasms Reclassified

7,046 studies on the registry are indexed under Prostatic Neoplasms; 1,580 are open to participants now.

This study's enrollment of 250 is above the median of 200 across 1,310 observational studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Hisar Intercontinental Hospital is the lead sponsor of 19 studies on the registry; none are open to participants now.

Compared within Prostatic Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Prostatic Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Adult male patients with acute prostatitis were included in the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Acute prostatitis Male

Exclusion criteria

-

Exclusion Criteria:

Prostate cancer Chronic prostatitis Other Urinary infections,

-

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
250 participants (actual)
Target follow-up
4 Years
Patient registry
Yes

Groups and cohorts

  • Group 1

    :PSA\<4 ng/mL

    Diagnostic Test: Serum PSA,Delta Neutrophil Index(DNI),WBC

  • Group 2

    PSA\>4 ng/mL

    Diagnostic Test: Serum PSA,Delta Neutrophil Index(DNI),WBC

Interventions

  • Diagnostic testSerum PSA,Delta Neutrophil Index(DNI),WBC

    Urine culture, prostate volume

    Also known as: MPV,NLR,RDW

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve (AUC)

    Time frame: 4 years

07

Study locations

1 site
  • Basri Cakiroglu
    Istanbul, 34768, Turkey
08

References and documents

Individual participant data

Plan to share: Yes — re

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05399940
Lead sponsor
Hisar Intercontinental Hospital
Responsible party
Basri Cakiroglu (Ass. Prof., Hisar Intercontinental Hospital) — Principal investigator
First posted
Jun 1, 2022
Start date
Jan 1, 2018
Primary completion
May 1, 2022
Completion
May 20, 2022
Last update
Jun 1, 2022

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion